Clinical trials: Overweight With Comorbidities
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- AZD6234
- Where
- 212 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
NAFLD, Obesity
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2…
- Conditions
- NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias
- Trial name
- NCT05872269
- Testing
- Saroglitazar
- Where
- 19 sites in India
- Volunteers
- 1,500 people
- Sponsor
- Zydus Lifesciences Limited
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial name
- KaiNETIC-1 (NCT07284875)
- Testing
- Ribupatide
- Where
- 110 sites in United States, Argentina and 8 more
- Volunteers
- 2,530 people
- Sponsor
- Kailera
Obesity
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities.
- Trial name
- NCT00386061
- Testing
- rimonabant (SR141716)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 1,507 people
- Sponsor
- Sanofi
Obesity, Overweight, or Chronic Weight Management
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at…
- Trial name
- ACCESS (NCT06693843)
- Testing
- Aleniglipron
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Trial name
- ATTAIN-CN (NCT07790861)
- Testing
- Orforglipron
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
A phase 3, multicenter, randomized, double-blind, double-dummy, parallel-group, active-drug- and placebo-controlled clinical trial to assess the safety, efficacy and superiority of the new fixed-dose combination sibutramine…
- Trial name
- UNLIMITED (NCT05209984)
- Testing
- ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg, ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg, SIB Group Sibus (Sibutramine) 15mg
- Where
- 2 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Obesity, Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing…
- Trial name
- NCT07752979
- Testing
- ABBV-295
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 360 people
- Sponsor
- AbbVie
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Chronic Weight Management
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
- Trial name
- NCT07002905
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity, Overweight
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are…
- Trial name
- NCT06525935
- Testing
- Enicepatide
- Where
- 34 sites in United States
- Volunteers
- 469 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Obesity
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
- Trial name
- ZUPREME (NCT06662539)
- Testing
- Petrelintide
- Where
- 32 sites in United States, Poland and 1 more
- Volunteers
- 493 people
- Sponsor
- Zealand Pharma
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
- Conditions
- Obesity, Overweight, Metabolism and Nutrition Disorder
- Trial name
- SURMOUNT-CN (NCT05024032)
- Testing
- Tirzepatide
- Where
- 29 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for…
- Trial name
- ASCEND (NCT06862791)
- Testing
- AZD9550, AZD6234
- Where
- 53 sites in United States, Australia and 3 more
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Overweight and Obesity
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
- Trial name
- NCT05051579
- Testing
- LY3502970
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company